As you may already know, there are already two separate companies requesting emergency FDA authorization for the COVID-19 vaccine. Both vaccines under consideration are well over the 50 percent effective required by the FDA as they have proven to be nearly 95 percent effective against COVID-19.

While we are expecting some logistical issues to come up the American Medical Association (AMA), in cooperation with the Centers for Disease Control and Prevention, have come up with two new CPT codes that we expect will be used to report future immunizations. The reason for two codes is that each code is unique to one of the vaccines under review.

The CPT codes account for the work related to vaccination such as the administration of the vaccine, counseling, and the documentation of the vaccine in the patient record.

At the time of this publication the codes are:

 91300: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease

[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use.

91301: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease

[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 100 mcg/0.5mL dosage, for intramuscular use.

For more information please visit:

https://www.ama-assn.org/amaone/cpt-current-procedural-terminology